Jazz Pharmaceuticals Public Limited Company (JAZZ)’s Chairman & CEO Bruce Cozadd Sold 3000 shares of the Company; Regal Entertainment Group (RGC)’s Sentiment Is 1.16

At an average price-per-share of $150.0, Bruce Cozadd, the Jazz Pharmaceuticals Plc’s Chairman & CEO made a sale of 3,000 shares of Jazz Pharmaceuticals Plc worth about $450,000 USD. At the moment, he owns 273,737 shares or 0.46% of the Company’s total market capitalization.

Regal Entertainment Group, together with its subsidiaries, operates as a motion picture exhibitor in the United States. The company has market cap of $3.59 billion. The firm develops, acquires, and operates multi-screen theatres primarily in mid-sized metropolitan markets and suburban growth areas of larger metropolitan markets. It has a 26.2 P/E ratio. It operates a theatre circuit under the brands of Regal Cinemas, United Artists, Edwards, Great Escape Theatres, and Hollywood Theaters.

Ratings analysis reveals 33% of Regal Entertainment’s analysts are positive. Out of 3 Wall Street analysts rating Regal Entertainment, 1 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. The lowest target is $22.0 while the high is $26.0. The stock’s average target of $24 is 4.44% above today’s ($22.98) share price. RGC was included in 3 notes of analysts from August 24, 2016. The company was initiated on Wednesday, August 24 by Loop Capital. Wedbush maintained Regal Entertainment Group (NYSE:RGC) on Friday, April 7 with “Outperform” rating. The firm earned “Underperform” rating on Wednesday, February 1 by Credit Suisse.

Rivulet Capital Llc holds 5.91% of its portfolio in Regal Entertainment Group for 3.11 million shares. Hamlin Capital Management Llc owns 4.34 million shares or 2.81% of their US portfolio. Moreover, New Mountain Vantage Advisers L.L.C. has 2.23% invested in the company for 1.82 million shares. The Illinois-based Coe Capital Management Llc has invested 1.95% in the stock. Polaris Capital Management Llc, a Massachusetts-based fund reported 1.78 million shares.

Analysts await Regal Entertainment Group (NYSE:RGC) to report earnings on February, 8. They expect $0.39 earnings per share, up 18.18% or $0.06 from last year’s $0.33 per share. RGC’s profit will be $60.98M for 14.73 P/E if the $0.39 EPS becomes a reality. After $0.07 actual earnings per share reported by Regal Entertainment Group for the previous quarter, Wall Street now forecasts 457.14% EPS growth.

The stock increased 0.35% or $0.08 during the last trading session, reaching $22.98. About 2.77 million shares traded. Regal Entertainment Group (RGC) has declined 1.35% since January 18, 2017 and is downtrending. It has underperformed by 18.05% the S&P500.

The stock decreased 0.06% or $0.09 during the last trading session, reaching $149.71. About 459,221 shares traded. Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) has risen 1.25% since January 18, 2017 and is uptrending. It has underperformed by 15.45% the S&P500.

Since August 10, 2017, it had 0 insider purchases, and 16 insider sales for $2.80 million activity. Gray Peter sold $102,078 worth of stock or 717 shares. MILLER MICHAEL PATRICK also sold $27,830 worth of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) shares. Sohn Catherine A. also sold $94,248 worth of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) on Thursday, August 10. Winningham Rick E had sold 662 shares worth $94,248. 662 Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) shares with value of $94,248 were sold by O’Keefe Kenneth W. The insider COZADD BRUCE C sold $153,520. McSharry Heather Ann sold $102,077 worth of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) on Thursday, August 10.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $8.98 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 24.65 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Among 21 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 16 have Buy rating, 0 Sell and 5 Hold. Therefore 76% are positive. Jazz Pharmaceuticals has $229 highest and $124 lowest target. $179.76’s average target is 20.07% above currents $149.71 stock price. Jazz Pharmaceuticals had 70 analyst reports since August 3, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, January 11 by BMO Capital Markets. Morgan Stanley initiated the shares of JAZZ in report on Thursday, October 5 with “Hold” rating. The stock of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) earned “Buy” rating by UBS on Wednesday, May 11. Cantor Fitzgerald maintained the shares of JAZZ in report on Tuesday, November 7 with “Buy” rating. FBR Capital maintained Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) rating on Wednesday, November 8. FBR Capital has “Buy” rating and $206.0 target. Bernstein initiated Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) rating on Wednesday, November 25. Bernstein has “Market Perform” rating and $160 target. Mizuho downgraded the shares of JAZZ in report on Thursday, April 6 to “Neutral” rating. Mizuho maintained Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) on Wednesday, February 24 with “Neutral” rating. Deutsche Bank maintained the shares of JAZZ in report on Monday, July 17 with “Buy” rating. The stock has “Buy” rating by Mizuho on Wednesday, May 11.

Investors sentiment decreased to 1.03 in Q3 2017. Its down 0.36, from 1.39 in 2017Q2. It fall, as 39 investors sold Jazz Pharmaceuticals Public Limited Company shares while 82 reduced holdings. 31 funds opened positions while 94 raised stakes. 53.58 million shares or 3.54% more from 51.74 million shares in 2017Q2 were reported. Dearborn Prns Limited Liability Company reported 1,753 shares. Alphaone Investment Svcs Ltd Limited Liability Company has invested 0.01% in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). Tower Rech Capital Limited Company (Trc) holds 879 shares. Ahl Prns Ltd Liability Partnership accumulated 24,265 shares or 0.06% of the stock. Fjarde Ap accumulated 0.05% or 17,669 shares. Highstreet Asset Management reported 2,907 shares stake. Manufacturers Life Insur Commerce The owns 384 shares. Reilly Fincl Advisors Limited Liability Corporation accumulated 23 shares. Fifth Third National Bank & Trust owns 195 shares or 0% of their US portfolio. Toronto Dominion Fincl Bank stated it has 2,535 shares or 0% of all its holdings. Lpl Financial Llc holds 0% or 3,609 shares. Citadel Advsrs Ltd Liability Co holds 0.07% of its portfolio in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) for 650,923 shares. Magnetar Limited Liability Co has invested 0.02% in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). Peak6 Investments Limited Partnership reported 0.02% in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). United Cap Fincl Advisers Limited Liability Corporation invested 0% of its portfolio in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ).